Hamman’s syndrome in diabetic ketoacidosis

Alexandra Rose Pain, Josh Pomroy and Andrea Benjamin
Charing Cross Hospital, Imperial College Healthcare Trust, London, UK

Summary
Hamman’s syndrome (spontaneous subcutaneous emphysema and pneumomediastinum) is a rare complication of diabetic ketoacidosis (DKA), with a multifactorial etiology. Awareness of this syndrome is important: it is likely underdiagnosed as the main symptom of shortness of breath is often attributed to Kussmaul’s breathing and the findings on chest radiograph can be subtle and easily missed. It is also important to be aware of and consider Boerhaave’s syndrome as a differential diagnosis, a more serious condition with a 40% mortality rate when diagnosis is delayed. We present a case of pneumomediastinum, pneumopericardium, epidural emphysema and subcutaneous emphysema complicating DKA in an eighteen-year-old patient. We hope that increasing awareness of Hamman’s syndrome, and how to distinguish it from Boerhaave’s syndrome, will lead to better recognition and management of these syndromes in patients with diabetic ketoacidosis.

Background
Hamman’s syndrome (spontaneous subcutaneous emphysema and pneumomediastinum) is a rare complication of diabetic ketoacidosis (DKA). It is important to consider Boerhaave’s syndrome as a differential diagnosis, particularly in patients with DKA and severe vomiting. Patients have similar symptoms, but Boerhaave’s syndrome is a more serious condition with a 40% mortality rate when diagnosis is delayed.

Case presentation
An eighteen-year-old man attended the Accidents & Emergency (A&E) department following six hours of vomiting. He was diagnosed with type 1 diabetes mellitus aged 8 years, controlled with an insulin pump. He had a recent HbA1c of 7.4% and no microvascular or macrovascular complications. He described coryzal symptoms, myalgia and headaches for one week prior to admission. He had no other significant past medical history, particularly no respiratory disease, and did not take any other regular medications. He was a non-smoker and did not take any illicit drugs. Prior to presenting to A&E, his blood glucose was 24 mmol/L, with urine ketones ++++.

Investigation
When reviewed in A&E, he was alert and orientated, with dry mucous membranes. On clinical examination,
he had Kussmaul’s breathing, was tachycardic, had enlarged non-exudative tonsils and anterior cervical non-tender lymphadenopathy. The rest of the clinical examination was unremarkable. His venous blood gas was as follows: pH: 7.39, Base Excess:18.7, pCO₂: 3.6 kPa, HCO₃: 16.3 mmol/L, lactate: 2.6 mmol/L and glucose: 27.5 mmol/L. Laboratory bloods showed WCC: 33.7 × 10⁹/L, CRP: 3.2 mg/L, K: 5.1 mmol/L, Na: 129 mmol/L, creatinine: 159 μmol/L, amylase: 34 U/L and capillary ketones: 5.1 mmol/L. Urine dip showed glucose ++++, ketones ++, blood +. A diagnosis of diabetic ketoacidosis (DKA), secondary to viral illness, was made and he was managed, as per hospital protocol, with intravenous fluids and a fixed rate insulin infusion.

Treatment
A diagnosis of diabetic ketoacidosis (DKA), secondary to viral illness, was made and he was managed, as per hospital protocol, with intravenous fluids and a fixed rate insulin infusion.

The next morning, he complained of neck pain, and on examination, he had mild surgical emphysema bilaterally in the supraclavicular fossae. A chest radiograph showed supraclavicular subcutaneous emphysema and pneumomediastinum (Fig. 1). A CT thorax with water-soluble oral contrast was performed and pneumomediastinum, pneumopericardium, epidural emphysema and surgical emphysema in the soft tissues of the neck and supraclavicular fossae, extending deep into the fascial planes below the pectoralis minor (Fig. 2). There was no contrast leak from the esophagus.

Outcome and follow-up
Following resolution of the DKA and review by a diabetologist to ensure correct pump function, he was discharged with an appointment for a repeat chest radiograph in six weeks and diabetic follow-up. He had no complications or lasting effects at 8 months.

Discussion
What is pneumomediastinum?
Pneumomediastinum is a rare complication of DKA. It is an accumulation of air within the mediastinum and can be primary/spontaneous or secondary to respiratory disease and trauma. High intrathoracic pressures lead to overdistension and rupture of alveoli, allowing air to leak and track along the bronchovascular bundles to the mediastinum (1). Air can then track to the subcutaneous tissues of the neck, the pericardium, retroperitoneum or through the posterior mediastinum and intervertebral foramen to the epidural space. Rupture of the mediastinal pleura can also lead to pneumothorax (2).

Pathogenesis of pneumomediastinum in DKA
The pathogenesis of pneumomediastinum in DKA is multifactorial. Kussmaul’s breathing, the respiratory compensation mechanism in metabolic acidosis,
increases the alveolar pressure 20–30 mmHg above normal inspiratory pressures, predisposing to alveolar rupture. Vomiting in DKA also increases intrathoracic pressures, secondary to the Valsalva maneuver. DKA is often associated with severe vomiting, especially in the first 24 h, caused by acidosis. Gastroparesis is also worsened by hyperglycaemia and exacerbates vomiting. Possibly contributing are the recently described fibrotic changes in the lungs of people with poorly controlled diabetes, predisposing to alveolar rupture at lower intrathoracic pressures (3).

**Symptoms and signs**

Symptoms include chest or neck pain and shortness of breath. Signs are subcutaneous emphysema, and Hamman’s sign – a precordial crunching or popping sound during systole, associated with 50% of cases (2).

**Diagnosis**

A diagnosis of pneumomediastinum can be made on chest radiograph. A CT thorax is necessary to look for esophageal rupture or mediastinitis. Boerhaave’s syndrome, the syndrome of esophageal perforation due to raised intraluminal pressures, can complicate violent vomiting and is occasionally seen in DKA (4, 5). Other sequelae of raised venous pressures secondary to violent vomiting, such as subconjunctival hemorrhage and facial petechiae, may be present and raise clinical suspicion of Boerhaave’s syndrome. Clinical judgment must be exercised as Boerhaave’s is a rare syndrome and CT gives high radiation doses to often young patients. A CT thorax with water-soluble oral contrast shows contrast leak, though care should be taken interpreting a negative result, since the high pressure during possible perforation will no longer be present.

**Management**

The management of Hamman’s syndrome in DKA involves reversal of the underlying cause. DKA guidelines advocate high dose fixed rate insulin to reverse the ketoacidosis quickly, thereby reducing the compensatory hyperventilation and antiemetics to manage vomiting. It is worth noting that gastroparesis may co-exist in patients with multiple diabetes complications, and these patients often respond better to prokinetic antiemetics such as metoclopramide and domperidone. If vomiting continues despite pharmacological interventions, consideration can be given to Ryles’ tube insertion. If Boerhaave’s syndrome is suspected, CT thorax, prompt intravenous antibiotics and liaison with the surgical team are essential.

Although a rare complication of DKA, Hamman’s syndrome is not currently mentioned as a complication in the Joint British Diabetes Societies (JBDS) DKA 2013 guidelines. Including it when the guidelines are next updated may lead to raised awareness and improved management.

**Prognosis**

Hamman’s syndrome associated with DKA has an excellent prognosis, self-resolving with the correction of the ketoacidosis in all published cases in the literature. When diagnosis and surgical intervention is delayed, Boerhaave’s syndrome has a high mortality of 40% (6).

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

**Patient consent**

Written, informed consent was obtained from the patient for the publication of this article.

**Author contribution statement**

All authors contributed equally to the design, writing and editing of the article.

**References**


Received in final form 6 October 2017
Accepted 8 November 2017